Cyanotech
This article was originally published in The Tan Sheet
Executive Summary
Nasdaq sends Cyanotech delisting warning letter June 18 for "failure to comply with the $1 minimum bid price." Company has until Sept. 16 to regain compliance. Also, FDA acknowledges receipt of May 28 joint letter from firm and Earthrise Nutritionals asking agency to stop evaluating ingredient spirulina as being GRAS for use in bars, powdered nutritional drink mixes while firms "clarify and prepare additional information for a new notice." Cyanotech and Earthrise jointly had submitted a GRAS petition for spirulina microalgae March 21 (1"The Tan Sheet" April 22, 2002, In Brief)...
You may also be interested in...
Banner laxative petition denied
Data presented by Banner Pharmacaps fails to show docusate calcium can be interchanged with docusate sodium, FDA says in a Nov. 17 letter. The firm asked in a 2002 petition that the two ingredients be considered interchangeable in OTC laxative drug product monograph combinations. (1"The Tan Sheet" June 24, 2002, In Brief). The agency says data are needed showing the bioavailability of docusate calcium relative to docusate sodium "is not affected when combined with sennosides A and B or sodium carboxymethylcellulose." The letter recommends firm contact the agency's OTC division before commencing new studies...
Spirulina GRAS filing
Cyanotech and Earthrise Nutritionals submit joint March 21 GRAS petition to FDA for use of Spirulina microalgae as an ingredient in bars, powdered nutritional drink mixes "at levels ranging from .5 to 3 g per serving size." Cyanotech currently markets Spirulina Pacifica dietary supplements in pure powder and tablet form...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.